Immunotherapy pioneer
Matthias Schroff, erstwhile CEO of Mologen, has taken over the helm of immunotherapy developer Vaximm AG. The Swiss-German company appointed him Chief Executive Officer in early September.
Before joining Vaximm, Schroff served as CEO of immuno-oncology pioneer Mologen AG for eight years. He was also on the Board of Directors of the biotech arm of the German Association of Research-based Pharmaceutical Companies (vfA bio).
Schroff holds a PhD in biochemistry from Freie Universität in Berlin and has numerous patents in the field of immuno-oncology, RNAi and gene expression to his name, including a TLR9 agonist that is now in late-stage clinical development for various cancer indications.
Adobe stock photos - https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/
X-act Cologne Clinical Research GmbH
NATO